Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Apr 21:4:e06670.
doi: 10.7554/eLife.06670.

The mucosal adjuvant cyclic di-GMP enhances antigen uptake and selectively activates pinocytosis-efficient cells in vivo

Affiliations

The mucosal adjuvant cyclic di-GMP enhances antigen uptake and selectively activates pinocytosis-efficient cells in vivo

Steven M Blaauboer et al. Elife. .

Abstract

Effective mucosal adjuvants enhance the magnitude and quality of the vaccine response. Cyclic di-GMP (CDG) is a promising mucosal vaccine adjuvant. However, its in vivo mechanisms are unclear. Here, we showed, in mice, that CDG elicits stronger Ab and TH responses than the mammalian 2'3'-cyclic GMP-AMP (cGAMP), and generated better protection against Streptococcus pneumoniae infection than 2'3'-cGAMP adjuvanted vaccine. We identified two in vivo mechanisms of CDG. First, intranasally administered CDG greatly enhances Ag uptake, including pinocytosis and receptor-mediated endocytosis in vivo. The enhancement depends on MPYS (STING, MITA) expression in CD11C(+) cells. Second, we found that CDG selectively activated pinocytosis-efficient-DCs, leading to T(H) polarizing cytokines IL-12p70, IFNγ, IL-5, IL-13, IL-23, and IL-6 production in vivo. Notably, CDG induces IFNλ, but not IFNβ, in vivo. Our study revealed previously unrecognized in vivo functions of MPYS and advanced our understanding of CDG as a mucosal vaccine adjuvant.

Keywords: STING; cell biology; dendritic cells; immunology; lung; mouse; mucosal adjuvant; pneumococcal vaccine.

PubMed Disclaimer

Conflict of interest statement

The authors declare that no competing interests exist.

Figures

Figure 1.
Figure 1.. Cyclic di-GMP (CDG) is a better mucosal pneumococcal vaccine adjuvant than the mammalian cyclic dinucleotide 2′3′-cyclic GMP-AMP (cGAMP) in mice.
(A) BALB/c mice were intranasally (i.n.) immunized with three doses (14 days apart) of OVA (20 μg) alone or together with 5 μg CDG or 5 μg 2′3′-cGAMP. Each group consisted of four mice. Sera or nasal washes from the 4 mice in the same group were pooled. Blood and nasal washes samples were collected 14 days after the last immunization. Anti-OVA IgG1, IgG2A, and IgA were quantified by ELISA. n = 3. (B) Splenocytes from immunized BALB/c mice were stimulated with 50 μg/ml OVA for 4 days in culture. Supernatants from the same group were pooled together. Cytokines were measured in the supernatant by ELISA. n = 3. (C) C57BL/6 mice were immunized with 3 doses of pneumococcal surface protein A (PspA) (2 μg) alone or together with 5 μg CDG or 5 μg 2′3′-cGAMP as in A. Blood and nasal washes were collected 14 days after the last immunization. Anti-PspA IgG1, IgG2C, and IgA were measured by ELISA as in A. n = 3. (D) Splenocytes from immunized C57BL/6 mice were stimulated with 5 μg/ml PspA for 4 days in culture. Cytokines were measured in the supernatant by ELISA as in B. n = 3. (E) Immunized mice were infected (i.n.) with S. pneumoniae (∼5.0 × 106 c.f.u.). At 48 hr post infection, lung and spleen bacterial burden were determined. n = 2. Graph present means ± standard error from three independent experiments. Significance is represented by an asterisk, where p < 0.05. DOI: http://dx.doi.org/10.7554/eLife.06670.003
Figure 2.
Figure 2.. CDG does not cause lung injury or excess inflammatory responses in vivo.
(A) C57BL/6 mice were treated (i.n.) with saline or CDG (5 μg) for 20 hr. Cells in Bronchoalveolar lavage fluid (BALF) were analyzed by FACScan with indicated Abs. Live cells were gated. n > 3. (B) Serum albumin level in the collected BALF was measured by ELISA (#GWB-282C17; GenWay). n = 3. (C) Lung sections from treated mice were fixed and histology was determined by Hematoxylin and eosin stain. n = 3. (DG) Mice were treated as in A. Lung cells were analyzed by FACScan with indicated Abs and quantified. Live cells were gated. n = 3. (HI) C57BL/6 and MPYS−/− mice were treated (i.n.) with saline or CDG (5 μg) for the indicated time. Cytokines were determined in lung homogenates by ELISA. n > 3. Graph present means ± standard error from three independent experiments. Significance is represented by an asterisk, where p < 0.05. DOI: http://dx.doi.org/10.7554/eLife.06670.004
Figure 3.
Figure 3.. CDG induces a variety of cytokines in lung that is dependent on the expression of MPYS.
(AE) C57BL/6 and Tmem173−/− mice were treated (i.n.) with saline or CDG (5 μg) for the indicated time. Cytokines were determined in lung homogenates by ELISA. n > 3. (FG) C57BL/6 mice were treated (i.n.) with saline or CDG (5 μg) for 5 hr. IL-12-p35 and IFNγ positive dendritic cells (DCs) were identified by intracellular cytokine stains and quantified. n = 3. Graph present means ± standard error from three independent experiments. Significance is represented by an asterisk, where p < 0.05. DOI: http://dx.doi.org/10.7554/eLife.06670.005
Figure 3—figure supplement 1.
Figure 3—figure supplement 1.. IFNλ production is dispensable for the mucosal adjuvant activity of CDG.
DOI: http://dx.doi.org/10.7554/eLife.06670.006
Figure 4.
Figure 4.. CDG enhances Ag uptake and activates pinocytosis-efficient antigen presenting cells (APCs) in vivo.
(AB) A cartoon showing mechanism of action of DQ-OVA (A) and OVA-647 (B). (C) Flow cytometry analysis of lung cells from C57BL/6 mice treated with saline, DQ-OVA(20 μg) + OVA-647(20 μg) or 5 μg CDG + DQ-OVA(20 μg) + OVA-647(20 μg) for 20 hr. Live cells were gated. n > 3. (D) Flow cytometry analysis of lung cells from C57BL/6 mice treated with OVA-647(20 μg) or 5 μg CDG + OVA-647(20 μg) for 20 hr. Live cells were gated. n > 3. (E) Flow cytometry analysis of lung APCs from C57BL/6 mice treated with 5 μg CDG + OVA-647(20 μg) for 20 hr. Live cells were gated. n > 3. (F) Histogram of OVA-647 signals from OVA-647+ APCs. n > 3. (G) Cell numbers of activated OVA-647+ APCs were quantified. n > 3. Graph present means ± standard error from three independent experiments. DOI: http://dx.doi.org/10.7554/eLife.06670.007
Figure 5.
Figure 5.. CDG generates mature DCs in vivo.
(A) Flow cytometry analysis of lung cells from C57BL/6 mice treated with saline, DQ-OVA(20 μg) + OVA-647(20 μg) or 5 μg CDG + DQ-OVA(20 μg) + OVA-647(20 μg). Live cells were gated. n > 3. (B) Histogram of DQ-Red and DQ-Green signals from indicated populations. n > 3. (C) Flow cytometry analysis of DQ+ lung cells from CDG + DQ-OVA treated (i.n.) C57BL/6 mice. Live DQ+ cells were gated. n > 3. (D) Flow cytometry analysis of lung cells from CDG + DQ-OVA treated (i.n.) C57BL/6 mice. Live cells were gated. n = 3. (E) Flow cytometry analysis of DQ+ lung cells from DQ-OVA or CDG + DQ-OVA treated (i.n.) C57BL/6 mice. Live were gated. n > 3. (F) Flow cytometry analysis of the indicated population from lung cells of CDG + DQ-OVA treated (i.n.) C57BL/6 mice. Gated on live DQ+ CD80+MHC II+ or live DQ+ CD86+MHC II+ cells. n > 3. DOI: http://dx.doi.org/10.7554/eLife.06670.008
Figure 6.
Figure 6.. CDG activates pinocytosis-efficient CD103+ and CD11B+ DCs in vivo.
(A and D) Flow cytometry analysis of lung cells from C57BL/6 mice treated (i.n.) with DQ-OVA (20 μg) or CDG (5 μg) + DQ-OVA (20 μg) for 20 hr. Live cells were gated. n > 3. (B and E) Flow cytometry analysis of DQ+ DCs from lung of CDG + DQ-OVA treated C57BL/6 mice. Cells were gated on live DQ+CD103+MHC II+ or live DQ+CD11B+MHC II+ cells. n > 3. (C and F) Histogram of DQ-Green and DQ-Red signals from cell populations in B and E. n > 3. (G) Total cell number of CD86+DQ+ DCs in lung. n = 3. (H and J) Flow cytometry analysis of lung draining lymph nodes (DLN) from DQ-OVA or CDG + DQ-OVA treated C57BL/6 mice. Live cells were gated. n = 3. (I and K) Flow cytometry analysis of DQ+ DCs in DLN of CDG + DQ-OVA treated C57BL/6 mice. Cells were gated on live DQ+CD103+MHC II+ or live DQ+CD11B+MHC II+ cells. n = 3. (LN) Total cell numbers of DCs, DQ+DCs, and CD86+DQ+DCs in DLN from DQ-OVA or CDG + DQ-OVA treated mice. n = 3. Graph present means ± standard error from three independent experiments. Significance is represented by an asterisk, where p < 0.05. DOI: http://dx.doi.org/10.7554/eLife.06670.009
Figure 7.
Figure 7.. MPYS is critical for CDG induced Ag uptake and activation in vivo.
(A) Flow cytometry analysis of lung cells from OVA-647(20 μg) or OVA-647(20 μg) + CDG(5 μg) treated (i.n.) C57BL/6 or Tmem173−/− mice. Live cells were gated. n > 3. (B) Flow cytometry analysis of lung cells from DQ-OVA (20 μg) or DQ-OVA(20 μg) + CDG(5 μg) treated (i.n.) C57BL/6 or Tmem173−/− mice. Live cells were gated. n > 3. (C and D) Flow cytometry analysis of lung cells from C57BL/6 or Tmem173−/− mice treated with saline, DQ-OVA(20 μg) or 5 μg CDG + DQ-OVA(20 μg). Live cells were gated. n > 3. (E) DQ+CD103+DCs and DQ+CD11B+DCs numbers from DQ-OVA or CDG + DQ-OVA treated C57BL/6 and Tmem173−/− mice. n = 3. (F) Flow cytometry analysis of DQ+ lung cells from DQ-OVA(20 μg) + CDG(5 μg) treated (i.n.) C57BL/6 or Tmem173−/− mice. Live DQ+ cells were gated. n > 3. (G) One month after the last immunization, CDG/PspA or PspA immunized WT and Tmem173−/− mice were infected (i.n.) with S. pneumoniae (D39 strain, ∼5.0 × 106 c.f.u.). At 48 hr post infection, lung bacterial burden was determined. n = 2. Graph present means ± standard error from three independent experiments. Significance is represented by an asterisk, where p < 0.05. DOI: http://dx.doi.org/10.7554/eLife.06670.010
Figure 8.
Figure 8.. CDG induced DC Ag uptake and activation requires MPYS expression in CD11C+ cells.
(A) Flow cytometry analysis of lung cells from DQ-OVA (20 μg) or DQ-OVA(20 μg) + CDG(5 μg) treated (i.n.) Tmem173Flox/Flox or ItgaxCre Tmem173Flox/Flox mice. Live cells were gated. n = 3. (B) Total DQ+ lung cells from DQ-OVA or CDG + DQ-OVA treated Tmem173Flox/Flox, ItgaxCre Tmem173Flox/Flox, and Tmem173−/− mice. n = 3. (C) DQ+ DCs numbers from DQ-OVA or CDG + DQ-OVA treated Tmem173Flox/Flox, ItgaxCre Tmem173Flox/Flox and Tmem173−/− mice. n = 3. (D and E) Flow cytometry analysis of DQ+ DCs from lung of DQ-OVA or CDG + DQ-OVA treated mice Tmem173Flox/Flox, ItgaxCre Tmem173Flox/Flox. Live cells were gated. n = 3. (FK) Tmem173Flox/Flox, ItgaxCreTmem173Flox/Flox or Tmem173−/− mice were treated with saline or CDG (5 μg) for 20 hr. Indicated cytokines were measured in lung homogenates by ELISA. n = 3. Graph present means ± standard error from three independent experiments. Significance is represented by an asterisk, where p < 0.05. DOI: http://dx.doi.org/10.7554/eLife.06670.011
Figure 8—figure supplement 1.
Figure 8—figure supplement 1.. Generation of ItgaxCreTmem173Flox/Flox mouse.
DOI: http://dx.doi.org/10.7554/eLife.06670.012
Figure 9.
Figure 9.. MPYS expression in CD11C+ cells is required for the optimal mucosal adjuvant activity of CDG.
(A) Tmem173Flox/Flox, ItgaxCreTmem173Flox/Flox or Tmem173−/− mice were intranasally administered OVA (20 μg) alone or together with 5 μg CDG as in Figure 1A. Anti-OVA IgG1, IgG2C and IgA were determined by ELISA. n = 3. (B) Tmem173Flox/Flox, ItgaxCreTmem173Flox/Flox or Tmem173−/− mice were immunized with PspA (2 μg) alone or together with 5 μg CDG as in Figure 1C. Anti-PspA IgG1, IgG2C, and IgA were measured by ELISA. n = 3. (CD) Splenocytes and lung cells from PspA or CDG + PspA immunized Tmem173Flox/Flox, ItgaxCreTmem173Flox/Flox or Tmem173−/− mice were stimulated with 5 μg/ml PspA for 4 days in culture. Cytokines were measured in the supernatant by ELISA as in Figure 1D n = 3. (E) 1 month after the last immunization, CDG/PspA or PspA immunized Tmem173Flox/Flox and ItgaxCreTmem173Flox/Flox mice were infected (i.n.) with S. pneumoniae (D39 strain, ∼5.0 × 106 c.f.u.). At 48 hr post infection, lung bacterial burden were determined. n = 2. Graph present means ± standard error from three independent experiments. Significance is represented by an asterisk, where p < 0.05. DOI: http://dx.doi.org/10.7554/eLife.06670.013
Figure 9—figure supplement 1.
Figure 9—figure supplement 1.. The impaired CDG response in ItgaxCreTmem173Flox/Flox mice is not due to the over-expression of Cre in CD11C+ cells.
DOI: http://dx.doi.org/10.7554/eLife.06670.014
Figure 10.
Figure 10.. In vivo mechanisms of the mucosal vaccine adjuvant CDG.
(A) The formula of CDG. Red arrows indicate the phosphate groups that prevent CDG from directly crossing the cell membrane. (B) Mechanism I: CDG enhances Ag uptakes in APCs and non-APCs. Among OVA647+APCs, only a portion of MHC IIhiCD11C+ (DCs) and MHC IIint CD11C cells up-regulate CD86 expression in vivo. They are mainly OVA647low cells, which take up Ag by pinocytosis. The activation of these cells generate a cytokine milieu that acts on other cells leading to enhanced Ag uptake (OVA647hi cells) but not cell activation. CDG also activates lung epithelial cells (LEC), leading to TSLP and IL-33 production. But this is only partially dependent on MPYS and is not sufficient to enhance Ag uptake in vivo (Figure 8). (C) Mechanism II: CDG selectively activates pinocytosis-efficient DCs in vivo. After administering DQ-OVA together with CDG, the DQ+MHC IIhiCD11C+ Ag-loading DCs can be separated into two distinct populations: DQ-Green+DQ-RedCD86+ and DQ-Green+DQ-Red+CD86. DQ-Green+DQ-Red cells are OVA-647low cells, while DQ-Green+DQ-Red+ cells are OVA-647hi cells. Only the DQ-Green+DQ-RedCD86+ cells migrated to lung DLNs. DOI: http://dx.doi.org/10.7554/eLife.06670.015
Author response image 1.
Author response image 1.
DOI: http://dx.doi.org/10.7554/eLife.06670.018
Author response image 2.
Author response image 2.
DOI: http://dx.doi.org/10.7554/eLife.06670.019

References

    1. Abdul-Sater AA, Tattoli I, Jin L, Grajkowski A, Levi A, Koller BH, Allen IC, Beaucage SL, Fitzgerald KA, Ting JP, Cambier JC, Girardin SE, Schindler C. Cyclic-di-GMP and cyclic-di-AMP activate the NLRP3 inflammasome. EMBO Reports. 2013;14:900–906. doi: 10.1038/embor.2013.132. - DOI - PMC - PubMed
    1. Ablasser A, Goldeck M, Cavlar T, Deimling T, Witte G, Röhl I, Hopfner KP, Ludwig J, Hornung V. cGAS produces a 2'-5'-linked cyclic dinucleotide second messenger that activates STING. Nature. 2013;498:380–384. doi: 10.1038/nature12306. - DOI - PMC - PubMed
    1. Blaauboer SM, Gabrielle VD, Jin L. MPYS/STING-mediated TNF-alpha, not type I IFN, is essential for the mucosal adjuvant activity of (3'-5')-cyclic-di-guanosine-monophosphate in vivo. The Journal of Immunology. 2014;192:492–502. doi: 10.4049/jimmunol.1301812. - DOI - PMC - PubMed
    1. Burdette DL, Monroe KM, Sotelo-Troha K, Iwig JS, Eckert B, Hyodo M, Hayakawa Y, Vance RE. STING is a direct innate immune sensor of cyclic di-GMP. Nature. 2011;478:515–518. doi: 10.1038/nature10429. - DOI - PMC - PubMed
    1. Burgdorf S, Kautz A, Bohnert V, Knolle PA, Kurts C. Distinct pathways of antigen uptake and intracellular routing in CD4 and CD8 T cell activation. Science. 2007;316:612–616. doi: 10.1126/science.1137971. - DOI - PubMed

Publication types